BRAF and rheumatoid arthritis: In this report, we developed indirect ELISAs on the basis of the recombinant catalytic domain of BRAF or the synthesized peptide P25 and determined the prevalence of autoantibodies to BRAF in patients with RA, pSS, or SLE and in healthy controls.